Semi-synthetic cannabinoid triggers severe psychosis in teens

Hexahydrocannabinol (HHC), a semi-synthetic cannabinoid that emerged as a legal alternative to traditional THC, has raised serious neuropsychiatric safety concerns. This case series reports two adolescents with no prior psychiatric history who experienced severe psychosis after using HHC, both requiring approximately six weeks of inpatient psychiatric hospitalization. Their symptoms resolved completely following discontinuation of HHC and treatment with antipsychotic medications, establishing a clear causal link between this emerging drug and acute psychotic episodes.

The cases highlight a critical public health concern: HHC products have proliferated in the legal market as consumers seek alternatives to regulated cannabis, yet the neuropsychiatric risks remain inadequately understood. Unlike well-studied cannabinoids such as THC and CBD, HHC's pharmacological effects and safety profile are not well-characterized, making it particularly risky for vulnerable populations like adolescents whose brains are still developing. The dual impact of symptom onset and clinical recovery aligned with substance use patterns strengthens the evidence for HHC as a direct causative agent in these cases.

These cases directly informed regulatory action, with HHC being banned in July 2025 due to emerging concerns about its safety. The findings underscore the importance of clinician awareness and the dangers of novel synthetic cannabinoids entering the market ahead of rigorous safety testing. For cannabis users and the general public, this case series serves as a cautionary tale about unregulated synthetic alternatives and emphasizes the value of evidence-based regulatory frameworks protecting public health.